Anti-ZNF33A monoclonal antibody

Pre-made anti-ZNF33A monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to ZNF33A/ZNF33A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2321-Ab-1/ GM-Tg-hg-IP2321-Ab-2Anti-Human ZNF33A monoclonal antibodyHuman
GM-Tg-rg-IP2321-Ab-1/ GM-Tg-rg-IP2321-Ab-2Anti-Rat ZNF33A monoclonal antibodyRat
GM-Tg-mg-IP2321-Ab-1/ GM-Tg-mg-IP2321-Ab-2Anti-Mouse ZNF33A monoclonal antibodyMouse
GM-Tg-cynog-IP2321-Ab-1/ GM-Tg-cynog-IP2321-Ab-2Anti-Cynomolgus/ Rhesus macaque ZNF33A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2321-Ab-1/ GM-Tg-felg-IP2321-Ab-2Anti-Feline ZNF33A monoclonal antibodyFeline
GM-Tg-cang-IP2321-Ab-1/ GM-Tg-cang-IP2321-Ab-2Anti-Canine ZNF33A monoclonal antibodyCanine
GM-Tg-bovg-IP2321-Ab-1/ GM-Tg-bovg-IP2321-Ab-2Anti-Bovine ZNF33A monoclonal antibodyBovine
GM-Tg-equg-IP2321-Ab-1/ GM-Tg-equg-IP2321-Ab-2Anti-Equine ZNF33A monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2321-Ab-1/ GM-Tg-hg-IP2321-Ab-2; GM-Tg-rg-IP2321-Ab-1/ GM-Tg-rg-IP2321-Ab-2;
GM-Tg-mg-IP2321-Ab-1/ GM-Tg-mg-IP2321-Ab-2; GM-Tg-cynog-IP2321-Ab-1/ GM-Tg-cynog-IP2321-Ab-2;
GM-Tg-felg-IP2321-Ab-1/ GM-Tg-felg-IP2321-Ab-2; GM-Tg-cang-IP2321-Ab-1/ GM-Tg-cang-IP2321-Ab-2;
GM-Tg-bovg-IP2321-Ab-1/ GM-Tg-bovg-IP2321-Ab-2; GM-Tg-equg-IP2321-Ab-1/ GM-Tg-equg-IP2321-Ab-2
Products NameAnti-ZNF33A monoclonal antibody
Formatmab
Target NameZNF33A
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-ZNF33A monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2321-Ag-1Recombinant multi-species ZN33A/ ZNF33A/ KOX2 protein


    Target information

    Target IDGM-IP2321
    Target NameZNF33A
    Gene ID7581
    Gene Symbol and SynonymsKOX2,KOX31,KOX5,NF11A,ZNF11,ZNF11A,ZNF33,ZNF33A,ZZAPK
    Uniprot AccessionQ06730
    Uniprot Entry NameZN33A_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000189180
    Target ClassificationN/A

    The target: ZNF33A, gene name: ZNF33A, also named as KOX2, KOX31, KOX5, NF11A, ZNF11, ZNF11A, ZNF33, ZZAPK. Predicted to enable DNA-binding transcription activator activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.